

# Takumi Kumai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4029211/publications.pdf>

Version: 2024-02-01

67  
papers

1,125  
citations

430874

18  
h-index

414414

32  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 705-716.	4.2	128
2	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 877-890.	4.2	126
3	Peptide vaccines in cancer – old concept revisited. <i>Current Opinion in Immunology</i> , 2017, 45, 1-7.	5.5	94
4	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress. <i>Frontiers in Pediatrics</i> , 2019, 7, 141.	1.9	73
5	Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. <i>Cancer Immunology Research</i> , 2017, 5, 72-83.	3.4	61
6	Cancer immunotherapy: moving forward with peptide T cell vaccines. <i>Current Opinion in Immunology</i> , 2017, 47, 57-63.	5.5	53
7	CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 697-705.	4.2	48
8	Designing therapeutic cancer vaccines by mimicking viral infections. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 203-213.	4.2	36
9	c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. <i>OncImmunology</i> , 2015, 4, e976077.	4.6	35
10	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. <i>OncImmunology</i> , 2016, 5, e1169356.	4.6	34
11	The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 455-466.	4.2	31
12	Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 191.	4.4	30
13	A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy. <i>Cellular Immunology</i> , 2019, 341, 103925.	3.0	28
14	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
15	Tumor-derived TGF- $\beta$ 2 and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. <i>Journal of Translational Medicine</i> , 2014, 12, 265.	4.4	25
16	Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 469-478.	4.2	25
17	Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 16280.	3.3	22
18	Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1091-1103.	4.2	20

#	ARTICLE	IF	CITATIONS
19	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 408-414.	2.1	19
20	Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2021619.	4.6	19
21	Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 989-999.	4.2	15
22	Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. <i>Head and Neck</i> , 2016, 38, 410-416.	2.0	14
23	Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1466771.	4.6	14
24	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. <i>Cancer Immunology Research</i> , 2018, 6, 617-627.	3.4	13
25	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	4.4	13
26	Effects of early nutritional intervention by a nutritional support team for patients with head and neck cancer undergoing chemoradiotherapy or radiotherapy. <i>Head and Neck</i> , 2021, 43, 514-519.	2.0	13
27	Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1856545.	4.6	13
28	Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. <i>Laboratory Investigation</i> , 2019, 99, 612-624.	3.7	12
29	A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2215-2225.	4.2	11
30	A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2301-2312.	4.2	11
31	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3421-3434.	4.2	11
32	Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein-Barr Virus Relation. <i>Microorganisms</i> , 2021, 9, 1381.	3.6	11
33	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	4.4	10
34	A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. <i>Cancer Science</i> , 2021, 112, 2705-2713.	3.9	6
35	Novel targets for natural killer/T-cell lymphoma immunotherapy. <i>Immunotherapy</i> , 2016, 8, 45-55.	2.0	5
36	IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. <i>Translational Oncology</i> , 2022, 18, 101358.	3.7	5

#	ARTICLE	IF	CITATIONS
37	A tumor metastasis-associated molecule <i>twist1</i> is a favorable target for cancer immunotherapy due to its immunogenicity. <i>Cancer Science</i> , 2022, 113, 2526-2535.	3.9	4
38	Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3467-3470.	0.5	3
39	Spontaneous Pneumomediastinum: Unusual Cause of Sore Throat. <i>Journal of Pediatrics</i> , 2020, 224, 176-177.	1.8	2
40	Recent Changes in Nasopharyngeal Flora of Children in Japan. <i>Advances in Oto-Rhino-Laryngology</i> , 2011, 72, 176-178.	1.6	1
41	Peripherally Inserted Central Venous Catheters Provide Safe and Easy Central Venous Access in Patients with Head and Neck Cancer. <i>Practica Otologica</i> , 2021, 114, 801-805.	0.0	1
42	Laryngeal recurrence of extranodal NK/T cell lymphoma. <i>EJHaem</i> , 2021, 2, 667-668.	1.0	1
43	Four Cases of Mumps with Laryngeal Edema. <i>Practica Otologica</i> , 2012, 105, 277-284.	0.0	1
44	19th International Symposium on Epstein-Barr Virus and Associated Diseases, 29-30 July 2021, Asahikawa, Japan. <i>Cancers</i> , 2022, 14, 2924.	3.7	1
45	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. <i>Practica Otologica, Supplement</i> , 2013, 137, 52-53.	0.0	0
46	Helper T-cell based immunotherapy combined with adjuvants in head and neck squamous cell carcinoma. <i>Journal of Japan Society of Immunology &amp; Allergology in Otolaryngology</i> , 2014, 32, 185-190.	0.0	0
47	Innovative immunotherapy for nasal NK/T-cell lymphoma. <i>Journal of Japan Society of Immunology &amp; Allergology in Otolaryngology</i> , 2018, 36, 15-22.	0.0	0
48	Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma. <i>Orl</i> , 2020, 82, 343-350.	1.1	0
49	A Study on 15 Cases of External Auditory Canal Carcinoma. <i>Practica Otologica</i> , 2021, 114, 373-378.	0.0	0
50	A Case of Lyme Disease with Peripheral Facial Nerve Palsy. <i>Practica Otologica</i> , 2021, 114, 231-234.	0.0	0
51	Clinical Study of 107 Hospitalized Patients with Peritonsillar Abscess. <i>Practica Otologica</i> , 2021, 114, 553-558.	0.0	0
52	Clinical Study of 107 Hospitalized Patients with Peritonsillar Abscess. <i>International Journal of Practical Otolaryngology</i> , 2021, 04, e11-e16.	0.2	0
53	Peripherally Inserted Central Venous Catheters Provide Safe and Easy Central Venous Access in Patients with Head and Neck Cancer. <i>International Journal of Practical Otolaryngology</i> , 2021, 04, e29-e33.	0.2	0
54	Concurrent chemoradiotherapy with cisplatin and docetaxel for head and neck squamous cell carcinoma. <i>Clinical Otolaryngology</i> , 2022, 47, 228-233.	1.2	0

#	ARTICLE	IF	CITATIONS
55	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. <i>Practica Otologica</i> , 2013, 106, 423-429.	0.0	0
56	Fifth Report of Hands-on Seminar on Basic Research for Clinicians at the 57 <sup>th</sup> Annual Meeting of the Japanese Rhinologic Society. <i>Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)</i> , 2019, 58, 152-158.	0.0	0
57	Five Cases of Primary Malignant Lymphoma of the Paranasal Sinus. <i>Nihon Bika Gakkai Kaishi (Japanese)</i> 107, 108-114.	0.0	0
58	A Case of Late-onset Laryngeal Stenosis After Burn and Inhalation Injury. <i>Koutou (the LARYNX JAPAN)</i> , 2019, 31, 34-39.	0.1	0
59	A Case of Adult T-cell Leukemia with a Laryngeal Tumor. <i>Koutou (the LARYNX JAPAN)</i> , 2020, 32, 73-78.	0.1	0
60	A Case of Secretory Carcinoma of the Submandibular Gland Harboring an <i>ETV6-X</i> Fusion Gene. <i>Practica Otologica</i> , 2020, 113, 787-792.	0.0	0
61	Perioperative response to surgical tracheostomy in new coronavirus-positive patients with COVID-19. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2021, , .	0.0	0
62	A Case of Thyroid-like Low Grade Nasopharyngeal Papillary Adenocarcinoma of the Posterior Nasal Septum. <i>Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)</i> , 2021, 60, 495-501.	0.0	0
63	Seventh Report of the Hands-on Seminar on Basic Research for Clinicians at the 59th Annual Meeting of the Japanese Rhinologic Society. <i>Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)</i> , 2021, 60, 566-570.	0.0	0
64	Removal of Coin Cell Lithium Battery Lodged in the Pediatric Pharyngoesophageal Junction by Rigid Esophagoscopy; a Case Report. <i>Archives of Academic Emergency Medicine</i> , 2022, 10, e4.	0.4	0
65	Central-part laryngectomy after laryngotracheal separation to manage pharyngocutaneous fistula: A case report and retrospective analysis of 12 cases. <i>Auris Nasus Larynx</i> , 2022, , .	1.2	0
66	A Case of Isolated Malleus Fracture Caused by Negative Pressure. <i>Practica Otologica</i> , 2022, 115, 485-489.	0.0	0
67	A Case of Nasolacrimal Duct Obstruction During S-1 Treatment For Breast Cancer. <i>Practica Otologica</i> , 2022, 115, 503-506.	0.0	0